Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Human Immunodeficiency Virus Infections Clinical Trial

Official title:
A Phase 3, Randomized, Open-label, Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With NRTIs in Antiretroviral Naive HIV-1 Infected Subjects

Status Completed

Clinical Trial Summary

The purpose of this study was to compare the safety and tolerability of the to-be-marketed lopinavir/ritonavir (LPV/r) tablet formulation with the marketed soft gel capsule (SGC) formulation and to compare the safety, tolerability, and antiviral activity of once daily (QD) and twice daily (BID) dosing of the LPV/r tablet formulation in combination with select nucleoside reverse transcriptase inhibitors (NRTIs) in patients who have not previously received antiretroviral treatment.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Acquired Immunodeficiency Syndrome
HIV Infections
Human Immunodeficiency Virus Infections
Immunologic Deficiency Syndromes
Virus Diseases

Clinical Trial Details

NCT number	NCT00262522
Study type	Interventional
Source	Abbott
Contact
Status	Completed
Phase	Phase 3
Start date	November 2005
Completion date	July 2008

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03563742` - A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection	Phase 3
Completed	`NCT00294918` - An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome	Phase 2/Phase 3
Completed	`NCT00888446` - Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid	Phase 2
Completed	`NCT00294164` - Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)	Phase 2/Phase 3
Active, not recruiting	`NCT00332306` - Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment	Phase 3
Completed	`NCT00727597` - A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT	Phase 3
Completed	`NCT02452242` - Safety, PK and PD Study of ABX464 in Untreated HIV Patients	Phase 2
Active, not recruiting	`NCT00376012` - Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis	Phase 3
Completed	`NCT00358917` - Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects	Phase 3
Completed	`NCT00749840` - Attitudes and Beliefs and the Steps of HIV Care	N/A